Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 3,401–3,500 of 15,747
COVID-19 Infections and Asthma
Palmon, P., Jackson, D. J., & Denlinger, L. C. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.10.072 · Cited by 35
“It is our general recommendation given the reduction in COVID-19 illness, need for hospitalization, and mortality in patients who have received vaccination that all patients with asthma, in the absence of contraindications, should receive vaccination against SARS-CoV2.(29,48)”
Ebinger, J. E., Fert‐Bober, J., Printsev, I., Wu, M. J., Sun, N., Figueiredo, J. C., Eyk, J. E. V., Braun, J. G., Cheng, S. C., & Sobhani, K. (2021) · medRxiv · doi:10.1101/2021.02.23.21252230 · Cited by 30
Bewley, K. R., Gooch, K. E., Thomas, K. M., Longet, S., Wiblin, N. R., Hunter, L. E., Chan, K., Brown, P. J., Russell, R. A., Ho, C. M. K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg7996 · Cited by 29
Mrak, D., Sieghart, D., Simader, E., Tobudic, S., Radner, H., Mandl, P., Göschl, L., Koblischke, M., Hommer, N., Wagner, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33036-y · Cited by 32
Weber, D. J., Al‐Tawfiq, J. A., Babcock, H. M., Bryant, K. A., Drees, M. L., Elshaboury, R. H., Essick, K., Fakih, M. G., Henderson, D. K., Javaid, W., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.322 · Cited by 34
Antonelli, M., Pujol, J. C., Chaudhari, A., Granerød, J., Canas, L. S., Graham, M. S., Kläser, K., Marc Modat, A., Molteni, E., Murray, B. A. K., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.02.015 · Cited by 32
Systematic review and meta-analysis of neonatal outcomes of COVID-19 vaccination in pregnancy
Zhang, D., Huang, T., Chen, Z., Zhang, L., Gao, Q., Liu, G., Zheng, J., & Ding, F. (2023) · Pediatric Research · doi:10.1038/s41390-022-02421-0 · Cited by 38
Persistent epigenetic memory of SARS-CoV-2 mRNA vaccination in monocyte-derived macrophages
Simonis, A., Theobald, S. J., Koch, A. E., Mummadavarapu, R., Mudler, J. M., Pouikli, A., Göbel, U., Acton, R., Winter, S., Albus, A., et al. (2025) · Molecular Systems Biology · doi:10.1038/s44320-025-00093-6 · Cited by 36
Tang, F., Hammel, I. S., Andrew, M. K., & Ruiz, J. G. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00166-0 · Cited by 34
Dash, G. C., Subhadra, S., Turuk, J., Parai, D., Rath, S., Sabat, J., Rout, U. K., Kanungo, S., Choudhary, H. R., Nanda, R. R., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27382 · Cited by 33
“As COVID‐19 vaccines do not provide 100% protection, postvaccination breakthrough infection is possible but rare.(10,11) Earlier studies have suggested that COVID‐19 vaccines might protect against the occurrence of severe illness and might help in preventing infection.”
Background(2022) · doi:10.1038/s41564-022-01092-1 · Cited by 98
Naveed, Z., Li, J., Wilton, J., Spencer, M., Naus, M., García, H. A. V., Kwong, J. C., Rose, C., Otterstatter, M. C., & Janjua, N. Z. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.799 · Cited by 33
Flisiak, R., Horban, A., Jaroszewicz, J., Kozielewicz, D., Mastalerz–Migas, A., Owczuk, R., Parczewski, M., Pawłowska, M., Piekarska, A., Simon, K. A., et al. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16230 · Cited by 36
Deng, L., Glover, C., Dymock, M., Pillsbury, A., Marsh, J., Quinn, H., Leeb, A., Cashman, P. M., Snelling, T., Wood, N., et al. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51619 · Cited by 33
Effectiveness of COVID‑19 vaccines and their challenges (Review)
Marfè, G., Perna, S., & Shukla, A. K. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10843 · Cited by 37
Vaccination is the most effective and best way to avoid the disease of COVID‐19
Lotfi, H., Mazar, M. G., Ei, N. M. H., Fahim, M., & Yazdi, N. S. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.946 · Cited by 36
“Two anaphylactic responses were observed in two national health workers who received the BNT162b2 vaccine on the second day of the vaccine trial.(35,36) In adults, the occurrence of myocarditis after the injection of the vaccine was observed, and the FDA and CDC considered the effectiveness of the vaccine (due to the…”
BackgroundRenal Side Effects of COVID-19 Vaccination
Zhang, J., Cao, J., & Ye, Q. (2022) · Vaccines · doi:10.3390/vaccines10111783 · Cited by 35
Olsen, R. J., Christensen, P. A., Long, S. W., Subedi, S., Hodjat, P., Olson, R., Nguyen, M., Davis, J. J., Yerramilli, P., Saavedra, M. O., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.07.002 · Cited by 31
Hazlewood, G. S., Pardo, J. P., Barnabe, C. C. M., Schieir, O., Barber, C. E. H., Bernatsky, S., Colmegna, I., Hitchon, C. A., Loeb, M. B., Mertz, D., et al. (2021) · The Journal of Rheumatology · doi:10.3899/jrheum.210288 · Cited by 35
Optimizing COVID-19 control with asymptomatic surveillance testing in a university environment
Brook, C. E., Northrup, G. R., Ehrenberg, A. J., Doudna, J. A., & Boots, M. (2021) · Epidemics · doi:10.1016/j.epidem.2021.100527 · Cited by 39
Zhang, W., Kedzierski, Ł., Chua, B. Y. L., Mayo, M. J., Lonzi, C., Rigas, V., Middleton, B. F., McQuilten, H. A., Rowntree, L. C., Allen, L. F., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01508-y · Cited by 31
Martin, C., Nazareth, J., Jarkhi, A., Pan, D., Das, M., Logan, N. A., Scott, S., Bryant, L., Abeywickrama, N., Adeoye, O., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101926 · Cited by 31
Are vaccines against COVID-19 tailored to the most vulnerable people?
Incalzi, R. A., Trevisan, C., Signore, S. D., Volpato, S., Fumagalli, S., Monzani, F., Bellelli, G., Gareri, P., Mossello, E., Malara, A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.066 · Cited by 31
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 35
“Notably, SM-102 and ALC-0315 are the crucial ionizable delivery components in the Moderna mRNA-1273 and Pfizer/BioNTech BNT162b2 vaccines for preventing coronavirus disease 2019 (COVID-19), respectively [23, 92, 93].”
BackgroundPolymyalgia rheumatica following COVID-19 vaccination: A case-series of ten patients
Ottaviani, S., Juge, P., Forien, M., et al. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105334 · Cited by 31
Rennert, L., Ma, Z., McMahan, C. S., & Dean, D. (2022) · Nature Communications · doi:10.1038/s41467-022-31469-z · Cited by 36
Yasin, A. İ., Aydın, S. G., Sümbül, B., Koral, L., Şimşek, M., Geredeli, Ç., Öztürk, A., Perkin, P., Demirtaş, D., Erdemoğlu, E., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-1248 · Cited by 30
Butt, A. A., Peng, Y., Shaikh, O. S., Mayr, F., & Omer, S. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1023 · Cited by 34
“The efficacy of the first two authorized vaccines, the Pfizer-BNT-162b2 and the Moderna-mRNA-1273 vaccines, in randomized phase 3 clinical trials was 94-95% in preventing symptomatic disease.[1, 2] In the real-world setting, effectiveness of these vaccines is similarly very high, consistently exceeding 90%.”
BackgroundPinato, D., Ferrante, D., J. Aguilar-Company, Bower, M., Salazar, R., Mirallas, O., Sureda, A., Bertuzzi, A., Brunet, J., Lambertini, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.036 · Cited by 32
Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers
Song, J. Y., Cheong, H. J., Kim, S. R., Lee, S. E., Kim, S. H., Noh, J. Y., Yoon, Y. K., Choi, W. S., Park, D. W., Sohn, J. W., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e110 · Cited by 31
Delivery of nucleic acids using nanomaterials
Qin, Y., Ou, L., Zha, L., Zeng, Y., & Li, L. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00160-0 · Cited by 37
“Moreover, two mRNA vaccines (mRNA-1273 and BNT162b2) based on ionizable lipids received historic emergency use approvals, which may indicate a regulatory advantage for ionizable lipids [43, 228].”
BackgroundMethodHarnessing synthetic biology for advancing RNA therapeutics and vaccine design
Pfeifer, B. A., Beitelshees, M., Hill, A. B., Bassett, J., & Jones, C. H. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00323-3 · Cited by 42
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants
Mambelli, F., de Araujo, A. C. V. S. C., Farias, J. P., de Andrade, K. Q., Ferreira, L. C. D. S., Minoprio, P. M. C., Leite, L. C. C., & Oliveira, S. C. (2025) · Pathogens · doi:10.3390/pathogens14010023 · Cited by 39
“% in preventing symptomatic COVID-19 after a two-dose immunization ChAdOx1-S and CoronaVac, two additional vaccines largely used in Brazil, around 70 and 50% protection against the virus [9,18–20].”
Kapłonek, P., Deng, Y., Lee, J. S.-L., Zar, H. J., Zavadska, D., Johnson, M., Lauffenburger, D. A., Goldblatt, D., & Alter, G. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101048 · Cited by 32
“Neutralizing antibodies were linked to protective immunity across all platforms during the initial Phase 2b/3 trials when the D614G strain dominated the global pandemic (3-6).”
Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
Mofaz, M., Yechezkel, M., Guan, G., Brandeau, M. L., Patalon, T., Gazit, S., Yamin, D., & Shmueli, E. (2022) · Emerging infectious diseases · doi:10.3201/eid2807.212330 · Cited by 31
Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future
Baldanti, F., Ganguly, N. K., Wang, G., Möckel, M., O'Neill, L. A. J., Renz, H. E., Ferreira, C. E. D. S., Tateda, K., & Pol, B. J. V. D. (2022) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2022.2045250 · Cited by 33
“In symptomatic patients, who may have a negative NAAT but whose clinical presentation is highly suggestive of SARS-CoV-2 and a diagnosis is required to enable medical care, a low-dose chest-computed tomography (CT) scan could be used to diagnose or rule out COVID-19 pathophysiology [40–42].”
BackgroundInfluentialPochtovyi, A. A., Kustova, D. D., Siniavin, A. E., Dolzhikova, I. V., Shidlovskaya, E. V., Геннадьевна, Ш. О., Vasilchenko, L. A., Glavatskaya, A. A., Kuznetsova, N. A., Iliukhina, A. A., et al. (2023) · Vaccines · doi:10.3390/vaccines11101533 · Cited by 33
Bouillon, K., Baricault, B., Botton, J., Jabagi, M.-J., Bertrand, M., Semenzato, L., Le Vu, S., Drouin, J., Dray-Spira, R., Weill, A., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000104 · Cited by 31
Mateo‐Urdiales, A., Alegiani, S. S., Fabiani, M., Pezzotti, P., Filia, A., Massari, M., Riccardo, F., Tallon, M., Proietti, V., Manso, M. D., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.25.2100507 · Cited by 28
Stimuli-responsive nanoparticle-nanofiber hybrids for drug delivery and photodynamic therapy
Kabay, G., Meydan, A. E., Eom, T., Shim, B. S., Mutlu, M., & Kaleli‐Can, G. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122442 · Cited by 35
Chuleerarux, N., Manothummetha, K., Moonla, C., Sanguankeo, A., Kates, O. S., Hirankarn, N., Phongkhun, K., Thanakitcharu, J., Leksuwankun, S., Meejun, T., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008530 · Cited by 52
“However, many immunocompromised patient populations, including people with MM, were not included in clinical trials of COVID-19 vaccines.(5,7,8) MM, caused by the abnormal proliferation of clonal plasma cells producing monoclonal immunoglobulin, is the second most common hematologic malignancy in the United States and…”
Kuzmina, A., Wattad, S., Khalaila, Y., Ottolenghi, A., Rosental, B., Engel, S., Rosenberg, E., & Taube, R. (2021) · iScience · doi:10.1016/j.isci.2021.103467 · Cited by 36
Chang, C. W., Music, N., Cheung, M. B., Rossignol, E. D., Bedi, S., Patel, H., Safari, M., Lee, C., Otten, G. R., Settembre, E. C., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.013 · Cited by 36
“Recently, mRNA vaccines have been evaluated in large human cohorts for efficacy in preventing symptomatic disease and reducing COVID-19 severity.(15,16) Compared with conventional protein vaccines, mRNA vaccines present unique advantages, including production of immunogenic antigens in native conformation in human cel…”
BackgroundSARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges
Wellens, J., Colombel, J., Satsangi, J. J., & Wong, S.-Y. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab046 · Cited by 32
High Recovery Chromatographic Purification of mRNA at Room Temperature and Neutral pH
Miklavčič, R., Megušar, P., Kodermac, Š. M., Bakalar, B., Dolenc, D., Sekirnik, R., Štrancar, A., & Černigoj, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814267 · Cited by 35
“4 g of mRNA, sufficient for approximately 24,000 doses of mRNA-1273 [39] or 80,000 doses of BNT162b2 [40] mRNA vaccines against SARS-CoV-2 in a single chromatographic run.”
InfluentialGambardella, J., & Santulli, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa145 · Cited by 30
Gepner, Y., Mofaz, M., Oved, S., Yechezkel, M., Constantini, K., Goldstein, N., Eisenkraft, A., Shmueli, E., & Yamin, D. (2022) · Communications Medicine · doi:10.1038/s43856-022-00090-y · Cited by 28
Hirani, R., Noruzi, K. A., Iqbal, A., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11112713 · Cited by 30
Lázaro-Frías, A., Pérez, P., Zamora, C., Sánchez‐Cordón, P. J., Guzmán, M. G., Luczkowiak, J., Delgado, R. B., Casasnovas, J. M., Estéban, M., & García‐Arriaza, J. (2022) · npj Vaccines · doi:10.1038/s41541-022-00440-w · Cited by 32
“The histopathological parameters were graded following a semi-quantitative scoring system as follows: (0) no lesion; (1) minimal lesion; (2) mild lesion; (3) moderate lesion; (4) severe lesion.”
MethodThrombotic events and COVID-19 vaccines
Brazete, C. S., Aguiar, A., Furtado, I., & Duarte, R. (2021) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0298 · Cited by 35
Coronavirus Disease 2019: Clinics, Treatment, and Prevention
Burkert, F. R., Lanser, L., Bellmann‐Weiler, R., & Weiß, G. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.761887 · Cited by 36
Return on Investment of the COVID-19 Vaccination Campaign in New York City
Sah, P., VILCHES, T. N., Moghadas, S. M., Pandey, A., Gondi, S., Schneider, E. C., Singer, J., Chokshi, D. A., & Galvani, A. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.43127 · Cited by 30
Grupper, A., Katchman, E. A., Ben‐Yehoyada, M., Rabinowich, L., Schwartz, D., Schwartz, I. F., Shashar, M., Halperin, T., Turner, D., Goykhman, Y., et al. (2021) · Clinical Transplantation · doi:10.1111/ctr.14478 · Cited by 29
“Three cohorts were included in the study: (1) Pre-transplant vaccination group (Pre-Tx Vac), composed of 19 consecutive adult kidney transplant recipients, who received full vaccination (two doses 21 days apart) at least 1 month prior to kidney transplantation, (2) Posttransplant vaccination group (Post-Tx Vac), compo…”
MethodPérez, P., Lázaro-Frías, A., Zamora, C., Sánchez‐Cordón, P. J., Astorgano, D., Luczkowiak, J., Delgado, R. B., Casasnovas, J. M., Estéban, M., & García‐Arriaza, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.824728 · Cited by 31
Luo, B., Li, J., Hou, X., Yang, Q., Zhou, Y., Ye, J., Wu, X., Feng, Y., Hu, T., Xu, Z. Z., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0288 · Cited by 31
“Preliminary results have demonstrated that the COVID-19 vaccines have acceptable safety and high efficacy [29].”
BackgroundGrunau, B. E., Asamoah-Boaheng, M., Lavoie, P. M., Karim, M. E., Kirkham, T. L., Demers, P. A., Barakauskas, V., Marquez, A. C., Jassem, A. N., O’Brien, S. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab938 · Cited by 35
Caiazzo, V., & Stimpfel, A. W. (2022) · Public Health · doi:10.1016/j.puhe.2022.03.017 · Cited by 32
Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.05.429759 · Cited by 34
Dar-Odeh, N. S., Abu-Hammad, O. A., Qasem, F., Jambi, S., Alhodhodi, A., Othman, A., Abu-Hammad, A., Al-Shorman, H. M., Ryalat, S., & Abu‐Hammad, S. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2039017 · Cited by 30
A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination
King, E., & Towner, E. (2021) · American Journal of Case Reports · doi:10.12659/ajcr.931478 · Cited by 30
AlQahtani, M., Bhattacharyya, S., Alawadi, A., Mahmeed, H. A., Sayed, J. A., Justman, J. E., El‐Sadr, W., Hidary, J. D., & Mukherjee, S. (2021) · Research Square · doi:10.21203/rs.3.rs-828021/v1 · Cited by 30
“To date, multiple vaccines have been developed around the world that utilize different technologies.(1-5) Clinical trials have demonstrated variable levels of protection against symptomatic COVID-19, the primary outcome for many of these studies.”
BackgroundWalker, J. L., Schultze, A., Tazare, J., Tamborska, A., Singh, B., Donegan, K., Stowe, J., Morton, C. E., Hulme, W. J., Curtis, H. J., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.010 · Cited by 30
“There was a small imbalance in the number of cases of Bell’s palsy between vaccinated and control groups in trials for mRNA vaccines BNT162b2 and mRNA-1273, although not for the adenovirusvectored ChAdOx1 vaccine [12,16,17].”
BackgroundDumont, R., Richard, V., Lorthe, E., Loizeau, A., Pennacchio, F., Zaballa, M.-E., Baysson, H., Nehme, M., Perrin, A., L’Huillier, A. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34616-8 · Cited by 41
Woldemeskel, B. A., Dykema, A. G., Garliss, C. C., Cherfils, S., Smith, K. N., & Blankson, J. N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156083 · Cited by 31
All organic nanomedicine for PDT–PTT combination therapy of cancer cells in hypoxia
Urazaliyeva, A., Kanabekova, P., Beisenbayev, A. R., Kulsharova, G., Atabaev, T. S., Kim, S., & Lim, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-68077-4 · Cited by 36
Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations
Power, J. R., Keyt, L. K., & ADLER, E. D. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2066522 · Cited by 37
“When exposed to COVID19 virus, vaccine-induced antibodies bind the viral envelope spike protein, which both inhibits viral binding to the host cell surface protein angiotensin-converting enzyme 2 (ACE2) – a necessary step for cell entry and infection – and targets virus for destruction [79].”
BackgroundElberry, M. H., Ahmed, H., Hamdallah, A., Abdella, W. S., Sayed, A., Ghaith, H. S., & Negida, A. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02626-w · Cited by 32
“Based on large-scale clinical trial results, the mRNA vaccine (BNT162b2) developed by Pfizer/BioNTech was the first vaccine to be granted FDA approval in December 2020 [4], and other vaccines soon followed in its footsteps following the publication of their trial results.”
BackgroundWaning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
Tong, X., McNamara, R. P., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Bertera, H. L., Chicz, T. M., Lévican, J., Poblete, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39189-8 · Cited by 39
New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
Nappi, E., Santis, M. D., Paoletti, G., Pelaia, C., Terenghi, F., Pini, D., Ciccarelli, M., Selmi, C. F., Puggioni, F., Canonica, G. W., et al. (2022) · Vaccines · doi:10.3390/vaccines10050716 · Cited by 30
Murray, M. J., McIntosh, M., Atkinson, C. E., Mahungu, T. W., Wright, E., Chatterton, W., Gandy, M., & Reeves, M. B. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.010 · Cited by 33
Gueguen, J., Colosio, C., Bello, A. D., Scemla, A., N’Guyen, Y., Rouzaud, C., Carvalho-Schneider, C., Gautier-Vargas, G., Tremolières, P., Eddine, A. J., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.03.020 · Cited by 38
Chan, W., Ho, Y.-H. T., Wong, C. K. H., Choi, C., Lam, K. O., Yuen, K.-K., Kwong, D. L. �., & Hung, I. F. (2021) · Vaccines · doi:10.3390/vaccines9070792 · Cited by 33
“7% of the 43,549 participants enrolled were reported to have cancer [18].”
BackgroundInnate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
Zhu, Q., Xu, Y., Wang, T., & Xie, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053437 · Cited by 34
Freund, O., Tau, L., Weiss, T. E., Zornitzki, L., Frydman, S., Jacob, G., & Bornstein, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268050 · Cited by 31
“Patients were considered vaccinated if the last vaccine dose was given at least 10 days before the first positive nasopharyngeal PCR test for SARS-CoV-2, as previous studies shown a protective effect starting 7 to 12 days after vaccinations [10, 20, 21].”
MethodAbu‐Halaweh, S. A., Alqassieh, R., Suleiman, A., Al-Sabbagh, M. Q., Abu-Halaweh, M., Alkhader, D., Abu-Nejem, R., Nabulsi, R., Al‐Tamimi, M., Alwreikat, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9090950 · Cited by 35
“Headaches were reported in 52% of vaccine recipients, and less than 2% of vaccine recipients reported severe systemic reactions [22].”
BackgroundResultInfluentialLee, D. S., Kim, J. W., Lee, K. L., Jung, Y. J., & Kang, H. W. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.007 · Cited by 32
Zwitterionic Polymer-Decorated Lipid Nanoparticles for mRNA Delivery in Mammalian Cells
Khunsuk, P.-O., Pongma, C., Palaga, T., & Hoven, V. P. (2023) · Biomacromolecules · doi:10.1021/acs.biomac.3c00649 · Cited by 31
Song, G., Yuan, M., Liu, H., Capozzola, T., Lin, R. N., Torres, J. L., He, W., Musharrafieh, R., Dueker, K., Zhou, P.-P., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115948 · Cited by 30
Nanoparticles and Antiviral Vaccines
Liu, S., Hu, M., Liu, X., Liu, X., Chen, T., Zhu, Y., Liang, T., Xiao, S., Li, P., & Ma, X. (2023) · Vaccines · doi:10.3390/vaccines12010030 · Cited by 40
“In clinical trials, mRNA-LNP vaccines demonstrated more than 90% effectiveness against the original SARS-CoV-2 strain and achieved long-lasting immune protection [140,141].”
Self-citationBarbhaiya, M., Levine, J. M., Siegel, C. H., et al. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05963-6 · Cited by 30
Meunier, L., Sanavio, M., Dumortier, J., Meszaros, M., Faure, S., Bedoya, J. U., Echenne, M., Boillot, O., Debourdeau, A., & Pageaux, G. (2022) · Liver International · doi:10.1111/liv.15258 · Cited by 35
COVID‐19: Risk Factors Associated with Infectivity and Severity
Fadl, N., Ali, E., & Salem, T. Z. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13039 · Cited by 36
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-García, J., O’Horo, J. C., Virk, A., Swift, M. D., Gordon, J. E., Speicher, L. L., et al. (2021) · Med · doi:10.1016/j.medj.2021.12.002 · Cited by 34
“6%) in preventing symptomatic COVID-19, with onset 7 or more days after the second dose.(2) mRNA-1273, an mRNA vaccine developed by Moderna, showed 94.”
Domi, M., Leitson, M., Gifford, D. R., Nicolaou, A., Sreenivas, K., & Bishnoi, C. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17224 · Cited by 29
“Food & Drug Administration (FDA) granted Emergency Use Authorization (EUA) for two mRNA vaccines in December of 2020, BNT162b2 and mRNA-1273, manufactured by Pfizer-BioNTech and Moderna, respectively.(7,8) Although two doses are required to achieve nearly 95% effectiveness, the vaccines were found to be effective in p…”
BackgroundPratama, N. R., Wafa, I. A., Budi, D. S., Sutanto, H., Asmarawati, T. P., Barlian Effendi, G., & Wungu, C. D. K. (2022) · Vaccines · doi:10.3390/vaccines10122180 · Cited by 30
“, 2021(24) Casecontrol South Africa 52,468 > 18 Omicron period N/A 0-13 days group 8 (5-11) days 14-27 days group 20 (17-24) days 1-2 months group 32 (29-34) days Ad26.”
Cabanillas, B., Akdiş, C. A., & Novak, N. (2021) · Allergy · doi:10.1111/all.14725 · Cited by 32
CRISPR-Cas13b-mediated suppression of HBV replication and protein expression
McCoullough, L. C., Fareh, M., Hu, W., Sozzi, V., Makhlouf, C., Droungas, Y., Lee, C. L., Takawy, M., Fabb, S. A., Payne, T. J., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.025 · Cited by 31
Opportunities for innovation: Building on the success of lipid nanoparticle vaccines
Huang, J. Y., Yuen, D., Mintern, J. D., & Johnston, A. P. R. (2021) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2021.101468 · Cited by 36
Calculating Apparent p K a Values of Ionizable Lipids in Lipid Nanoparticles
Hamilton, N. B., Arns, S., Shelley, M. Y., Bechis, I., & Shelley, J. C. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00426 · Cited by 31
Nkosi, T., Chasara, C., Mbatha, A., Nsimbi, M., Papadopoulos, A. O., Nguni, T. L., Karim, F., Moosa, M. Y. S., Gazy, I., Jambo, K., et al. (2022) · eLife · doi:10.7554/elife.78374 · Cited by 35
“The research community rapidly mobilized and developed vaccines and therapeutics at unprecedented speed (Polack et al., 2020; Ball, 2021).”
BackgroundČerná, K., Ďuricová, D., Lukáš, M., Machková, N., Hrubá, V., Mitrová, K., Kubíčková, K., Kostrejová, M., Teplan, V., Vašátko, M., et al. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab301 · Cited by 30
COVID-19 and liver injury: An ongoing challenge
Papagiouvanni, I., Kotoulas, S., Pataka, A., Spyratos, D. G., Porpodis, Κ., Boutou, A., Papagiouvannis, G., Grigoriou, I., Vettas, C., & Goulis, I. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.257 · Cited by 33
Emerging and re-emerging pediatric viral diseases: a continuing global challenge
Hoffman, S. A., & Maldonado, Y. (2023) · Pediatric Research · doi:10.1038/s41390-023-02878-7 · Cited by 41
Current progress and challenges in the design and development of a successful COVID-19 vaccine
Li, T., Zhang, T., Gu, Y., Li, S., & Xia, N. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.011 · Cited by 31
Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
Hulme, W. J., Williamson, E., Horne, E. M. F., Green, A. C. A., McDonald, H. I., Walker, A. J., Curtis, H. J., Morton, C. E., MacKenna, B., Croker, R., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m21-4269 · Cited by 45
Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death
Chang, S. C., Gopal, P., Lim, S., Wei, X., Chandramohan, A., Mangadu, R., Smith, J., Ng, S., Gindy, M., Phan, U., et al. (2022) · Cell Chemical Biology · doi:10.1016/j.chembiol.2022.10.005 · Cited by 31
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.